Why Scholar Rock Holding Stock Soared Today
The market celebrated Scholar Rock's upsized stock offering and plans to advance development of a new obesity treatment. Here's what investors need to know.
Source: fool.com
📰 Jay Backstrom News
Page 2 - Jay Backstrom News Today
Fast, Ad-Free News Updates
Stay updated with breaking news from Jay Backstrom. Real-time updates on events, politics, business and more.
Scholar Rock Announces Completion of Enrollment for the Phase 3 SAPPHIRE Trial
Topline data from Phase 3 trial expected in Q4 2024 Company to present encore 36-month efficacy, safety, and patient-reported outcomes data from the Phase 2 TOPAZ trial extension at the 2023...
North Charleston South Carolina United States Jay Backstrom Thomaso Crawford Johns Hopkins University
Source: marketscreener.com
Scholar Rock Reports Second Quarter 2023 Financial Results and Highlights Business Progress
- Recently presented 36-month apitegromab extension data from Phase 2 TOPAZ trial demonstrate long-term substantial and sustained improvement of motor function and further strengthen conviction in...
Jay Backstrom Ted Myles Oncology Program Exchange Commission Scholar Rock Inc Scholar Rock Holding Corporation
Source: marketscreener.com
Scholar Rock Reports First Quarter 2023 Financial Results and Highlights Business Progress
- Enrollment of pivotal Phase 3 SAPPHIRE trial evaluating apitegromab on track for completion in 2023 - Upcoming presentations of 36-month apitegromab data from Phase 2 TOPAZ trial at Cure... | May 9, 2023
United States Ted Myles Jay Backstrom Richard Brudnick Muscular Dystrophy Association Exchange Commission
Source: marketscreener.com
Scholar Rock Reports Full Year 2022 Financial Results and Highlights Business Progress
CAMBRIDGE, Mass.--(BUSINESS WIRE)--Scholar Rock (NASDAQ: SRRK), a Phase 3 clinical-stage biopharmaceutical company focused on the treatment of serious diseases in which protein growth factors play
Source: finanznachrichten.de
Scholar Rock Provides Corporate Update and Highlights Priorities for 2023
09.01.2023 - Scholar Rock (NASDAQ: SRRK), a Phase 3 clinical-stage biopharmaceutical company focused on the treatment of serious diseases in which protein growth factors play a fundamental role, today provided recent corporate updates and highlighted upcoming ... Seite 1
Source: wallstreet-online.de
Scholar Rock Appoints Jing L. Marantz, M.D., Ph.D., M.B.A., as Chief Medical Officer
09.11.2022 - Scholar Rock (NASDAQ: SRRK), a Phase 3, clinical-stage biopharmaceutical company focused on the treatment of serious diseases in which protein growth factors play a fundamental role, today announced the appointment of Jing L. Marantz, M.D., Ph.D., ... Seite 1
Jay Backstrom Head Of Medical Affairs At Acceleron Pharma Head Of Medical Affairs At Alnylam Pharmaceuticals Global Affairs Us Medical Affairs Millennium Pharmaceuticals
Source: wallstreet-online.de
New Phase 2 TOPAZ Trial Data Indicate Positive Trends in Quality-of-Life Measures Over 24 Months with Apitegromab for Nonambulatory Patients with Types 2 and 3 SMA - Scholar Rock Holding (NASDAQ:SRRK) - Press Release
- Tertiary endpoint data show trends of continuous improvement in activities of daily living, fatigue, and endurance over 24 months - These data indic
United States Comunidad Autonoma De Cataluna Jay Backstrom Basil Darras Scholar Rock Inc International Scientific Congress
Source: wiredprnews.com
Scholar Rock Announces New Employment Inducement Grant Under Nasdaq Listing Rule 5635(c)(4)
22.09.2022 - Scholar Rock (NASDAQ: SRRK), a Phase 3 clinical-stage biopharmaceutical company focused on the treatment of serious diseases in which protein growth factors play a fundamental role today announced that the company granted equity awards as a material ...
Jay Backstrom Exchange Commission Scholar Rock Inc Scholar Rock Holding Registered Stock Grant Date Stock Option Award
Source: wallstreet-online.de
LAVA Therapeutics Announces Tw - GuruFocus.com
GuruFocus Article or News written by GuruFocusNews and the topic is about:
United States Jay Backstrom James Noble Acceleron Pharma Bristol Myers Squibb Celgene University Of Oxford
Source: gurufocus.com